SHERIDAN, WYOMING – November 09, 2024-Terumo Corporation, a leading medical technology company, has raised its financial forecast for the fiscal year ending March 31, 2025. This comes on the heels of impressive first-half results and favorable shifts in foreign exchange rates.
The company now anticipates consolidated revenue of 1.01 trillion yen, a 30 billion yen increase from its previous estimate. This upward revision reflects better-than-expected revenue in the first and second quarters, coupled with the yen's depreciation exceeding initial projections.
"Terumo's strong performance is fueled by robust growth across its various business segments, including Cardiac and Vascular, General Hospital, and Blood and Cell Technologies," said a company spokesperson. "The company's innovative products and global presence have allowed it to effectively meet the growing worldwide demand for healthcare solutions."
In addition to increased revenue, Terumo expects improved profitability. Adjusted operating profit, operating profit, and profit attributable to owners of the parent are all projected to surpass previous guidance. This is largely due to the revenue growth, ongoing cost control measures, and the positive impact of foreign exchange rate fluctuations.
"Terumo's dedication to innovation remains a cornerstone of its success," said the spokesperson. "The company continues to invest in research and development, creating cutting-edge medical devices and technologies that enhance patient outcomes. This commitment to advancing healthcare has solidified Terumo's position as a trusted partner for healthcare providers across the globe."
Looking forward, Terumo maintains a positive outlook for the rest of the fiscal year. The company is confident in its ability to navigate the evolving healthcare landscape and achieve sustainable growth. With its strong financial foundation and strategic focus, Terumo is well-equipped to continue generating value for its stakeholders and contributing to the advancement of healthcare worldwide.
About Terumo Corporation
Terumo Corporation is a leading global medical device company headquartered in Tokyo, Japan. Committed to contributing to society through healthcare, Terumo provides innovative solutions and services in various fields, including cardiology, vascular surgery, general hospital care, blood transfusion, and cell therapy. The company operates in over 160 countries and employs more than 28,000 people worldwide.